Key terms

About NEXI

NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke on June 7, 2011 and is headquartered in Gaithersburg, MD.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest NEXI news

Apr 05 4:24pm ET NexImmune Announces Leadership Shift in Financial Management Feb 06 5:07am ET NexImmune Announces New Offerings in Recent Press Release Feb 06 5:07am ET NexImmune Delays Liquidation Vote for Financing Review Feb 06 5:07am ET NexImmune Equity Sales: Unregistered Securities and Private Placement Feb 06 5:06am ET NexImmune Secures Funding Through Equity and Warrant Sales Feb 02 2:13pm ET Neximmune announces $3.67M registered direct offering priced at-the-market Feb 02 2:10pm ET Neximmune terminates equity sales agreement and ATM program Feb 02 2:10pm ET Neximmune Inc trading resumes Feb 02 2:00pm ET Neximmune Inc trading halted, volatility trading pause Jan 31 9:41am ET Neximmune Inc trading resumes Jan 31 9:36am ET Neximmune Inc trading halted, volatility trading pause Jan 30 9:57am ET Neximmune Inc trading resumes Jan 30 9:57am ET Neximmune Inc trading resumes Jan 30 9:52am ET Neximmune Inc trading halted, volatility trading pause Jan 29 12:09pm ET Neximmune Inc trading resumes Jan 29 12:04pm ET Neximmune Inc trading halted, volatility trading pause Jan 10 9:42am ET Neximmune Inc trading resumes Jan 10 9:37am ET Neximmune Inc trading halted, volatility trading pause Jan 09 9:44am ET Neximmune Inc trading resumes Jan 09 9:34am ET Neximmune Inc trading halted, volatility trading pause

No recent press releases are available for NEXI

NEXI Financials

1-year income & revenue

Key terms

NEXI Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

NEXI Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms